Drug Study (Mucosulvan, Verorab, Tetanus Toxoid)
GENERIC NAME: Anti-tetanus serum BRAND NAME: Tetanus Toxoid GENERAL CLASSIFICATION: EPI vaccine, Anti-tetanus INDICATION: ?Tetanus Toxoid is indicated for booster injection only for persons 7 yrs of age and older against tetanus. ?Primary immunization schedule for children under 7 yrs of age should consist of five doses of vaccine containing tetanus toxoid. ?Tetanus Toxoid is not to be used for treatment of tetanus infection. ?As with any vaccine, vaccination with tetanus toxoid may not protect 100% of susceptible individuals.
DOSAGES: ?After the initial immunization series is completed, a booster dose of 0. 5mL of tetanus toxoid should be given intramuscularly every 10 yrs to maintain adequate immunity. SIDE EFFECT/ ADVERSE REACTION: oBody System as a whole: Redness, warmth, edema, induration with or without tenderness as well as urticaria, and rash. Malaise, transient fever, pain, hypotension, nausea, and arthralgia NURSING CONSIDERATION: ?Shake well the vial before withdrawing each dose Special care should be taken to ensure that the injection does not enter the blood vessel ? For Nursing Mothers: Tetanus Toxoid does not affect the safety of mothers who are breastfeeding or their infants. Breastfeeding does not adversely affect immune response and is not a contraindication for vaccination ? For Pediatric Use: Safety and effectiveness of tetanus toxoid in infants below the age of 6 weeks has not been established. However, this vaccine is not indicated for children under 7 yrs of age.
?For Geriatric Use:Tetanus Toxoid should only be used in geriatric patients known to have received a primary series of tetanus-containing vaccine, since many such as persons have no prior immunity. “Verorab” GENERIC NAME: Rabies vaccine BRAND NAME: Verorab GENERAL CLASSIFICATION: Anti-rabies vaccine INDICATION: ?All subjects at a permanent risk should be vaccinated ?A serological test is recommended every 6 months ?A booster injection should be administered if the antibody titer is below the level considered to guarantee protection: 0. 5iu/mL DOSAGES: Primary Vaccination: 3 injections on days 0, 7 and 28. Booster injection 1 year later then every 5 years. ?Vaccination for non-immunized subjects:
The dosage is the same for adults and children. Includes five 0. 5mL injections on days 0, 3, 7, 14 and 28. SIDE EFFECT/ ADVERSE REACTION: ?Minor local reactions such as pain, erythema, edema, pruritus, induration at the injection site ? Systemic reactions such as fever, shivering, faintness, asthenia, headaches, dizziness, nausea, abdominal pains, rash NURSING CONSIDERATION: Use with caution on patients with a known allergy to neomycin ? Do not inject by the intravascular route ?Immunoglobulins and rabies vaccine must not be associated in the same syringe or injected at the same site ? For immunodeficient subjects, this may be conducted 2-4 weeks following the vaccination “Mucosolvan” GENERIC NAME: Ambroxol Hydrochloride BRAND NAME: Mucosolvan and Mucoangin GENERAL CLASSIFICATION: Expectorant INDICATION: ?Secretolytic therapy in bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport.DOSAGES: ?Adults: daily dose of 30 mg (one Ambroxol tablet )to 120 mg (4 Ambroxol tablets) taken in 2 to 3 divided doses ? Children up to 2 years: half a teaspoonful Ambroxol syrup twice daily ? Children 2 – 5 years: half a teaspoonful Ambroxol syrup 3 times daily ? Children over 5 years: One teaspoonful Ambroxol syrup 2-3 times daily.
SIDE EFFECT/ ADVERSE REACTION: ?Occasional gastrointestinal side effects may occur but these are normally mild. NURSING CONSIDERATION: ?Inform the doctor If the patient is suffering from a febrile illness, an acute
